PURPOSE: To evaluate prospectively duration and effectiveness of aperistalsis achieved by glucagon(GLU) or hyoscine N-butylbromide(HBB) following various administration routes. MATERIALS AND METHODS:Six volunteers underwentMagnetic Resonance Imaging (MRI) after standardized oral preparation in random order five separate MR examinations with both spasmolytic agents (HBB intravenous(i.v.) or intramuscular(i.m.), GLU i.v. or i.m., and a combined scheme). The MR protocol included a sagittal 2D cross-section of the small bowel with a temporal resolution of 0.55 s acquired over 60 to 90 min. To quantify bowel motility, small bowel cross-sectional areas were summated over time. RESULTS: The anti-peristaltic i.v. effects of HBB and glucagon started on average after 85 s/65 s and ended after 21 min/23.3 min, respectively. By comparison, the anti-peristaltic effects of i.m. HBB and glucagon started significantly later 5.1/11.6 min (P = 0.001; Wilcoxon signed ranks test) and lasted for 17.7/28.2 min with greater inter-individual differences (P = 0.012; Brown-Forsythe test). The combined scheme resulted in a rapid onset after 65 s with effect duration of 31 min. CONCLUSION: Anti-peristaltic effects on the small bowel are drug dependant, i.e., their onset is faster and more reliable when administering i.v. than i.m.. Combining i.v. GLU with i.m. HBB provides an early onset of effect, sustained spasmolysis and the highest degree of motility impairment. KEY POINTS: • Anti-persitaltic agents are widely used before various diagnostic procedures of the abdomen. • The combination of iv-glucagon with im-hyoscine provides reliable spasmolysis with early onset. • Intravenous spasmolysis is more reliable compared to intramuscular administration. • Intravenous glucagon has a prolonged spasmolytic effect compared to intravenous hyoscine.
RCT Entities:
PURPOSE: To evaluate prospectively duration and effectiveness of aperistalsis achieved by glucagon(GLU) or hyoscine N-butylbromide(HBB) following various administration routes. MATERIALS AND METHODS: Six volunteers underwent Magnetic Resonance Imaging (MRI) after standardized oral preparation in random order five separate MR examinations with both spasmolytic agents (HBB intravenous(i.v.) or intramuscular(i.m.), GLU i.v. or i.m., and a combined scheme). The MR protocol included a sagittal 2D cross-section of the small bowel with a temporal resolution of 0.55 s acquired over 60 to 90 min. To quantify bowel motility, small bowel cross-sectional areas were summated over time. RESULTS: The anti-peristaltic i.v. effects of HBB and glucagon started on average after 85 s/65 s and ended after 21 min/23.3 min, respectively. By comparison, the anti-peristaltic effects of i.m. HBB and glucagon started significantly later 5.1/11.6 min (P = 0.001; Wilcoxon signed ranks test) and lasted for 17.7/28.2 min with greater inter-individual differences (P = 0.012; Brown-Forsythe test). The combined scheme resulted in a rapid onset after 65 s with effect duration of 31 min. CONCLUSION: Anti-peristaltic effects on the small bowel are drug dependant, i.e., their onset is faster and more reliable when administering i.v. than i.m.. Combining i.v. GLU with i.m. HBB provides an early onset of effect, sustained spasmolysis and the highest degree of motility impairment. KEY POINTS: • Anti-persitaltic agents are widely used before various diagnostic procedures of the abdomen. • The combination of iv-glucagon with im-hyoscine provides reliable spasmolysis with early onset. • Intravenous spasmolysis is more reliable compared to intramuscular administration. • Intravenous glucagon has a prolonged spasmolytic effect compared to intravenous hyoscine.
Authors: Johannes M Froehlich; Michael A Patak; Constantin von Weymarn; Christoph F Juli; Christoph L Zollikofer; Klaus-Ulrich Wentz Journal: J Magn Reson Imaging Date: 2005-04 Impact factor: 4.813
Authors: Cynthia Schmidt; Andreas M Hötker; Urs J Muehlematter; Irene A Burger; Olivio F Donati; Borna K Barth Journal: Abdom Radiol (NY) Date: 2021-03-26
Authors: Michael R Torkzad; Gabriele Masselli; Steve Halligan; Aytek Oto; Henning Neubauer; Stuart Taylor; Arun Gupta; Jens Brøndum Frøkjær; Ian C Lawrance; Christopher J Welman; Anne Negård; Olle Ekberg; Michael Patak; Thomas Lauenstein Journal: Insights Imaging Date: 2015-04-09
Authors: Carlos Eduardo Oliveira Dos Santos; Hamilton Moreira; Julio Carlos Pereira-Lima; Carmen Australia Paredes Marcondes Ribas; Fernanda de Quadros Onófrio; Alexandre Eduardo Augusti Czecko; Rafael Koerich Ramos; Caroline Aragão de Carvalho Journal: Clinics (Sao Paulo) Date: 2017-07 Impact factor: 2.365
Authors: S A Taylor; F Avni; C G Cronin; C Hoeffel; S H Kim; A Laghi; M Napolitano; P Petit; J Rimola; D J Tolan; M R Torkzad; M Zappa; G Bhatnagar; C A J Puylaert; J Stoker Journal: Eur Radiol Date: 2016-10-18 Impact factor: 5.315
Authors: Asseel Khalaf; Caroline L Hoad; Robin C Spiller; Penny A Gowland; Gordon W Moran; Luca Marciani Journal: World J Gastrointest Pathophysiol Date: 2015-11-15